FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company Profile10x Genomics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TXG
10x Genomics, Inc. Stock AnalysisComprehensive stock analysis for 10x Genomics, Inc. (TXG) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTXG
TXG
10x Genomics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TXG
  1. Home
  2. Stocks
  3. 10x Genomics, Inc.

10x Genomics, Inc.

🇺🇸TXG•NASDAQ

10x Genomics, Inc.

🇺🇸TXG•NASDAQ
Market cap
$6.29B

Your view on TXG

Mkt Cap
$6.29B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About 10x Genomics, Inc.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
CEO
Serge Saxonov
Headquarters
6230 Stoneridge Mall Road, Pleasanton, CA, US
Industry
Medical - Healthcare Information Services
Sector
Healthcare
CEO
Serge Saxonov
Headquarters
6230 Stoneridge Mall Road, Pleasanton, CA, US
Description

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.

The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment.

The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions.

The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for 10x Genomics, Inc.. Starting points for 10x Genomics, Inc.: EPS -$0.51, beta 2.03 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for 10x Genomics, Inc.. Trailing twelve-month EPS for 10x Genomics, Inc. stands at -$0.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$71.83average of 12 firms, last 12 months
Current price—

Hold

Targets, low to high

$71.83

Low $17.00

Middle $70.00

High $110.00

Analyst ratings

13 firms, last 12 months
  • Strong Buy0
  • Buy5
  • Hold8
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.22−$0.18−$0.63−$0.67
Lowest estimate−$0.34−$0.26−$0.66−$1.12
Highest estimate$0.11−$0.03−$0.58$0.01
Number of analysts3278
A year ago−$0.13−$0.101−$0.351—
Growth vs a year ago−68.8%———

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$177.74M$167.60M$629.64M$703.27M
Lowest estimate$173.23M$156.15M$621.01M$670.33M
Highest estimate$182.45M$179.27M$637.07M$735.54M
Number of analysts1071112
A year ago$166.03M$150.84M$642.82M—
Growth vs a year ago+7.1%+11.1%−2.1%—
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for 10x Genomics, Inc.. 10x Genomics, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold TXG20 companies · 8 funds
Compare TXG with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AAgilent Technologies, Inc.HealthcareMedical - Diagnostics & Research$48.0B
BIOBio-Rad Laboratories, Inc.HealthcareMedical - Devices$9.7B
GNNSFGenscript Biotech CorporationHealthcareBiotechnology$3.8B
ILMNIllumina, Inc.HealthcareMedical - Diagnostics & Research$29.2B
LABStandard BioTools Inc.HealthcareMedical - Specialties$225.0M
QGENQiagen N.V.HealthcareMedical - Diagnostics & Research$10.2B
RVTYRevvity, Inc.HealthcareMedical - Diagnostics & Research$16.2B
TECHBio-Techne CorporationHealthcareBiotechnology$11.4B
More Medical - Healthcare Information Services companies
TickerTypeCompanySectorExchangeMkt cap
BTSGUBrightSpring Health Services, Inc. Tangible Equity UnitHealthcareNASDAQ$13.7B
CCLDCareCloud, Inc.HealthcareNASDAQ$101.3M
CERTCertara, Inc.HealthcareNASDAQ$1.7B
CGNSFCognetivity Neurosciences Ltd.HealthcareOTC$8,959
CGS.AXCogstate LimitedHealthcareASX—
CHS.VComprehensive Healthcare Systems, Inc.HealthcareTSXV$7.1M
CMHSFComprehensive Healthcare Systems, Inc.HealthcareOTC$9.8M
CMPDCompuMed, Inc.HealthcareOTC$6.3M
CNONFLynx Global Digital Finance CorporationHealthcareOTC$1,071
COGZFCogstate LimitedHealthcareOTC$259.0M
CRVWCareView Communications, Inc.HealthcareOTC$14.6M
CRWRFCraneware plcHealthcareOTC$850.6M
ETFs holding 10x Genomics, Inc.
TickerFundFund assets% of the fund
ARKKARK Innovation ETF$7.9B in assets2.62%
IWMiShares Russell 2000 ETF$76.6B in assets0.24%
VTIVanguard Total Stock Market ETF$689.2B in assets0.01%
VBVanguard Small-Cap ETF$76.9B in assets0.10%
PTHInvesco Dorsey Wright Healthcare Momentum ETF$293M in assets3.07%
QMOMAlpha Architect U.S. Quantitative Momentum ETF$400M in assets1.64%
CPAINorthern Lights Fund Trust III - Counterpoint Quantitative Equity ETF$550M in assets1.59%
PSCPrincipal U.S. Small-Cap Multi-Factor ETF$2.6B in assets0.85%

Largest holders first, then the funds most concentrated in TXG.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold 10x Genomics, Inc., and how their positions are changing. At a $6.29B market value, institutional positions materially move 10x Genomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by 10x Genomics, Inc. executives and directors. Shares of 10x Genomics, Inc. have traded between $6.78 and $17.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for 10x Genomics, Inc.. Coverage tracks 10x Genomics, Inc. within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of 10x Genomics, Inc.

TXG AnalysisGood
Past
5
Growth
3
Health
5
Profit
1
Value
1